T38170 |
RMC-0331
|
2488788-52-7
|
99.81%
|
|
RMC-0331 (RM-023) is an orally available and potent SOS1 inhibitor.RMC-0331 has potential anticancer activity, blocking RAS activation by disrupting RAS-SOS1 int...
|
T6895 |
TAK-580
|
1096708-71-2
|
99.77%
|
|
TAK-580 (MLN2480) is an oral, selective pan-Raf kinase inhibitor in Clinicalal trials.
|
T2624 |
OSI-930
|
728033-96-3
|
99.76%
|
|
OSI-930, an orally active inhibitor of c-Kit and the vascular endothelial growth factor receptor-2 (VEGFR-2), targets cancer cell proliferation and blood vessel ...
|
T8721L |
I-37 free base( 2359690-13-2(free base))
|
T8721L
|
99.75%
|
|
I-37 free base is a novel benzylamino substituted pyridopyrimidinone as SOS1 inhibitor.
|
T6487 |
Encorafenib
|
1269440-17-6
|
99.74%
|
|
Encorafenib (LGX818) is an orally available mutated BRaf V600E inhibitor(IC50=0.3 nM) with potential antineoplastic activity.
|
T13037 |
Sulindac sulfide
|
49627-27-2
|
99.68%
|
|
Sulindac sulfide (cis-Sulindac sulfide) is a non-steroidal anti-inflammatory compound that has a high affinity for COX-1 and acts as an inhibitor in Ras activati...
|
T8006 |
Oncrasin-1
|
75629-57-1
|
99.68%
|
|
Oncrasin 1 is a potent inhibitor of anticancer that kills various human lung cancer cells with K-Ras mutations at low or submicromolar concentrations
|
T4133 |
CCT196969
|
1163719-56-9
|
99.65%
|
|
CCT196969 is a novel orally available, pan-RAF inhibitor with anti-SRC activity. It also inhibits SRC, LCK, and the p38 MAPKs.
|
T6277 |
Doramapimod
|
285983-48-4
|
99.65%
|
|
Doramapimod (BIRB 796) is a highly potent inhibitor of p38 MAPK (Kd: 0.1 nM), but weakly inhibits c-RAF, Fyn, Lck, ERK-1, SYK, IKK2, and ZAP-70.
|
T2382 |
Vemurafenib
|
918504-65-1
|
99.65%
|
|
Vemurafenib (RG7204) is a B-RAF inhibitor that inhibits RAFV600E and c-RAF-1 (IC50=31/48 nM) selectively and potently. Vemurafenib exhibits antitumor activity an...
|
T8746L |
I-49 free base
|
T8746L
|
99.64%
|
|
I-49 free base (Pyrido[4,3-d]pyrimidin-7(6H)-one, 2-methyl-4-[[(1R)-1-[2-methyl-3-(trifluoromethyl)phenyl]ethyl]amino]-6-(tetrahydro-2H-pyran-4-yl)-) is a novel ...
|
T0093L |
Sorafenib
|
284461-73-0
|
99.61%
|
|
Sorafenib (Bay 43-9006) is a multikinase inhibitor that inhibits Raf-1, B-Raf, VEGFR2, VEGFR3, VEGFR4, PDGFRβ, FLT3, c-Kit, and others (IC50=6/22/90/15/20/20/57/...
|
T2293 |
SGX-523
|
1022150-57-7
|
99.6%
|
|
SGX-523 is a selective Met inhibitor (IC50: 4 nM), no inhibitory to Abl, BRAFV599E, p38α, and c-Raf.
|
T79830 |
B-Raf IN 16
|
2304746-24-3
|
99.56%
|
|
B-Raf IN 16, a BRAF inhibitor, belongs to cyclic iminopyrimidine derivatives and can be used for cancer or tumour research.
|
T6882 |
LY3009120
|
1454682-72-4
|
99.54%
|
|
LY3009120 (DP-4978) is a potent pan-Raf inhibitor with IC50 of 44 nM, 31-47 nM, and 42 nM for A-raf, B-Raf, and C-Raf in A375 cells, respectively. Phase 1.
|
T2473 |
PLX-4720
|
918505-84-7
|
99.5%
|
|
PLX-4720 is a potent and selective inhibitor of B-Raf (V600E) (IC50: 13 nM), equally potent to c-Raf-1(Y340D and Y341D mutations).
|
T1792L |
Regorafenib monohydrate
|
1019206-88-2
|
99.47%
|
|
Regorafenib Monohydrate is a novel oral multikinase inhibitor with IC50 values of 13, 4.2, 46, 22, 7, 1.5, 2.5, 28, 19 nM for VEGFR1, murine VEGFR2, murine VEGFR...
|
T19802 |
B-Raf IN 11
|
918504-27-5
|
99.46%
|
|
B-Raf IN 11 is a novel selective inhibitor. The DFG-in conformation of the B-Raf kinase V600E mutant is superior to the DFG-out conformation in colorectal cancer...
|
T8474 |
Dabrafenib Mesylate
|
1195768-06-9
|
99.45%
|
|
Dabrafenib Mesylate (GSK2118436 Mesylate) is a B-Raf inhibitor(IC50s of 0.6 and 5.0 nM for RafV600E and c-Raf, respectively).
|
T6555 |
K-Ras(G12C) inhibitor 12
|
1469337-95-8
|
99.44%
|
|
K-Ras(G12C) inhibitor 12 is an allosteric inhibitor of oncogenic K-Ras(G12C).
|